By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    headphones can create health problems
    The Harmful Health Effects of Using Headphones
    September 24, 2021
    Headache causes
    4 Causes Of Headache You Probably Didn’t Know About
    December 28, 2021
    follow these steps to recover from your injury
    What Steps Should You Take to Recover More Quickly from an Injury?
    April 12, 2022
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    private
    Private Exchanges: Getting Ready for Individual Health Insurance to Be the Standard
    January 9, 2014
    valueable healthcare programs
    5 Most Valuable Healthcare Programs in 2023
    March 8, 2023
    Johnson & Johnson to Release Clinical Trial Data in Agreement with Yale Medical School
    February 4, 2014
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 22, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 22, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 22, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Obesity Drug Development and Market Outlook
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > Obesity Drug Development and Market Outlook
Global HealthcarePublic Health

Obesity Drug Development and Market Outlook

PatrickDriscoll
PatrickDriscoll
Share
6 Min Read
SHARE

Researchers theorize that the current increasing prevalence of obesity is primarily driven by the combination of sedentary lifestyles (i.e. the increasing prevalence of desk jobs over physical jobs, as well as lack of exercise during free time) and changes in diets, especially in developed countries. To date, pharmaceutical treatments have shown poor success rates. Efficacy has been lower than hoped for, with at best about 3-5% weight loss—not to be confused with percentage of excess weight loss, or %EWL, which is the clinical measure of obesity treatment success or failure.

Researchers theorize that the current increasing prevalence of obesity is primarily driven by the combination of sedentary lifestyles (i.e. the increasing prevalence of desk jobs over physical jobs, as well as lack of exercise during free time) and changes in diets, especially in developed countries. To date, pharmaceutical treatments have shown poor success rates. Efficacy has been lower than hoped for, with at best about 3-5% weight loss—not to be confused with percentage of excess weight loss, or %EWL, which is the clinical measure of obesity treatment success or failure.

Nevertheless, driven by the staggering potential market size, companies continue to work to develop efficacious and relatively safe pharmaceutical treatments for obesity. (See Report #S835 for specific drug candidates and products in development, on the market, or recently withdrawn market, and the current and future market status for these drugs, as well as devices for obesity management.)

More Read

Overview of the FDA Approval Process
Medical Tests or Procedures That May Be Unnecessary
The Latest Numbers on Exchange Enrollment
Threatened by Domestic Violence? There’s an App for That
Proposed Medicare for All Bill Could Change Healthcare Billing Logistics

Source: MedMarket Diligence, LLC

Pharmaceuticals for the treatment of obesity fall into a number of categories based on their functional approach to treating the condition.  These include appetite suppression, malabsorption, satiety and combinations of these (e.g., Orexigen’s Contrave).  There is some debate in the clinical literature as to whether there is adequate distinction between appetite suppression and satiety to consider them functionally different drugs.

Other drugs, such as Amylin’s Byetta, have been shown to reduce weight loss as a function of its role in managing type 2 diabetes.

Trials for pharmaceutical treatment of obesity are aggressive as drug makers aggressively seek to generate clinical data on drugs already developed that will illustrate safety and efficacy, an increasingly difficult hurdle to cross (some would say “moving target”) based on the past rejections by the FDA.

Given the challenges of past drug candidates in gaining approval, and considering the untapped opportunity for obesity drugs, companies are actively pursuing multiple alternative angles to solving the obesity drug challenge:

  • melanocortin receptor system
  • cannabinoid receptor antagonists
  • GLP-1 analogs
  • methionine aminopeptidase 2 (MetAP2) inhibitor

In order to be judged effective the FDA holds that an obesity drug must meet at least one of two endpoints:

  • At least 35% or more of patients on the drug must lose at least 5% of their body weight. This weight loss must be twice that for placebo, and the results must be statistically significant.
  • There must be ≥ 5% difference in the mean weight loss between the active product and the placebo group, and again the results must be statistically significant.

The FDA also says that it will look at several secondary efficacy endpoints. These include blood pressure, pulse, lipoprotein lipids, and fasting glucose and insulin. However, the FDA does not limit itself to these, and may examine other metabolic parameters. The manufacturer might not learn what those other parameters are until the time of the review, and perhaps not until receiving a negative recommendation from the committee reviewing the drug, and reading the complete response letter (CRL).

With regard to obesity drugs, the FDA appears to take the position that the patients who would receive such drugs are basically healthy, so any weight management product must not only show decent efficacy, it must have no risk of causing lasting and/or serious harm to the patient. Some marketing managers say that it should come as no great surprise that drugs which appeared to be strong contenders for approval—such as Vivus’ Qnexa and Arena’s lorcaserin—received negative recommendations, given the uncertainty involved in trying to adhere to ‘draft’ guidelines. These managers also point out that the FDA routinely approves pharmaceuticals for the market which are known to have side effects, apparently judging that the cure is less harmful than the disease. Is there, then, a degree of bias within the FDA against the pharmaceutical treatment of obesity? If so, is this situation likely to improve? Whether or not a bias exists, we forecast that during the next five years, the FDA will approve several drugs for the treatment of obesity.


See further details of the pharmaceutical industry’s development of obesity drugs at link.

     

TAGGED:global healthobesitypublic health
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025
physiotherapist at work
How One Fall Can Lead to a Long Road of Medical Complications
Health care
August 20, 2025
Common Healthcare Accreditation Programs
7 Most Common Healthcare Accreditation Programs: Which Should You Use?
Health News
August 20, 2025

You Might also Like

Innovations in Care Delivery Models and the Role of Physician Incentives

November 18, 2012

FDA Shuts Down over 1600 Web Sites Selling Counterfeit and SubStandard Drugs

June 29, 2013

Lessons on Healthcare and Risks from the Passing of Joan Rivers

September 7, 2014
BusinessHealth ReformHospital AdministrationPolicy & LawPublic Health

Expansion of Primary Care and Relationships Leads to Fewer ER Visits

January 6, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?